A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date6/14/17 → 1/11/23

Funding

  • AbbVie Incorporated: $953,210.00